What is the prevalence of Goodpasture syndrome?

Goodpasture syndrome is a rare autoimmune disorder with an estimated annual incidence of approximately 1 case per million people, though true numbers may be higher due to underdiagnosis. It primarily affects adults, with a bimodal age distribution often peaking in the third and sixth decades of life, and it shows a distinct clinical preference for males over females.

Is Goodpasture syndrome considered a rare disease?

Yes, Goodpasture syndrome is classified as a rare disease. Because it is an autoimmune condition involving anti-glomerular basement membrane (anti-GBM) antibodies, it is infrequent in the general population. While exact global prevalence is difficult to determine because many cases are only identified after severe renal or pulmonary crisis, epidemiological data consistently categorizes Goodpasture syndrome as an orphan disease. At DiseaseMaps.org, we currently support a community of 108 individuals living with the condition, which provides a vital, real-world perspective on the rarity and personal impact of this diagnosis.

What are the incidence and gender distribution patterns?

The incidence of Goodpasture syndrome is estimated at roughly 0.5 to 1.0 per million individuals per year in Western populations. Clinical data indicates a notable gender disparity: men are more frequently affected than women, often by a ratio of approximately 2:1. Researchers believe this may be linked to hormonal factors or specific genetic predispositions, though the exact mechanism remains under investigation. While the condition can occur at any age, it is rarely diagnosed in children, with the most common onset occurring in two distinct age groups:

• Young adults: Primarily individuals in their 20s and 30s.


• Older adults: Individuals in their 60s and 70s.

Are there geographic or ethnic variations?

There is limited evidence suggesting that Goodpasture syndrome may have a higher incidence in certain populations, particularly those with specific human leukocyte antigen (HLA) types, such as HLA-DRB1*15:01. While the disease is observed globally, some studies have noted a higher prevalence in populations of European descent compared to others. However, it is crucial to note that geographic data is often skewed by the availability of specialized diagnostic testing, such as renal biopsies and serum anti-GBM antibody assays, which are not universally accessible.

Why is it difficult to track exact prevalence data?

Accurate epidemiological tracking for Goodpasture syndrome is challenged by several factors:

1. Underdiagnosis: Patients with mild or localized symptoms may not be tested for anti-GBM antibodies, leading to missed diagnoses.


2. Misdiagnosis: The clinical presentation often overlaps with other forms of rapidly progressive glomerulonephritis or pulmonary hemorrhage syndromes, leading to initial misclassification.


3. Diagnostic Latency: Because Goodpasture syndrome can progress rapidly, some patients may succumb to the illness before a definitive diagnosis is confirmed, complicating mortality and prevalence statistics.

Next steps

• Consult a nephrologist or pulmonologist immediately if you exhibit signs of sudden kidney dysfunction or unexplained respiratory issues.


• Request specialized testing for anti-GBM antibodies if Goodpasture syndrome is suspected by your clinical team.


• Connect with the 108 members of the DiseaseMaps.org community to share experiences and find peer support.


• Participate in rare disease registries to help researchers gather more accurate data on the long-term outcomes of this condition.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• Orphanet: Goodpasture syndrome (ORPHA:378).


• NIH Genetic and Rare Diseases Information Center (GARD): Anti-glomerular basement membrane disease.


• National Kidney Foundation: Information on Anti-GBM Disease.


• PubMed/NCBI: Epidemiological reviews on the incidence of anti-glomerular basement membrane disease.